Sunday 18 October 2026
Export APMD’s income statement to Excel — free account
Apnimed, Inc.
APMD
Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024. Insiders bought in the last twelve months.
17.76
0.49
−2.68%
Follow APMD
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 65 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.59 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 8 | 38 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 57.95 | 82.60 | |||||
| EBT | — | — | — | — | — | — | — | — | (109) | (58) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | (1,354.84) | (150.91) | |||||
| Net income | — | — | — | — | — | — | — | — | (111) | (128) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 1.69 | 8.08 | ||||
| Earnings | — | — | — | — | — | — | — | — | (23.46) | (26.91) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (23.23) | (16.34) | |||||
| Capex | — | — | — | — | — | — | — | — | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (23.25) | (16.34) | |||||
| Book value | — | — | — | — | — | — | — | — | (52.41) | (78.27) | |||||
| Shares, m | — | — | — | — | — | — | — | — | 5 | 5 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 1.27 | 1.27 | ||||
| P/S | — | — | — | — | — | — | — | — | 1.02 | 1.02 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.23 | 0.23 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.32) | (0.32) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (110) | (78) | ||||
| Capex | — | — | — | — | — | — | — | — | 0 | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (110) | (78) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 31 | (66) | ||||
| Total debt | — | — | — | — | — | — | — | — | — | 41 | |||||
| Net debt | — | — | — | — | — | — | — | — | (68) | (1) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (249) | (373) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (140.79) | ||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 41.26 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 7 Oct 2026
Charts ten years each
Apnimed, Inc. vs peers (Q) = latest quarter vs a year earlier
Apnimed, Inc. (APMD) key facts
- Concern: Apnimed, Inc. reported a net loss of $128.2 million, or a loss of $26.91 per share, for fiscal 2025.
- Strength: Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024.
- As of October 16, 2026, APMD traded at $17.76, a market capitalization of $759.6 million.
- At that price the stock trades at 0.9× trailing-twelve-month earnings and 0.7× sales.
- Return on equity was 41.3% and debt-to-equity -0.45.